Enovis (NYSE:ENOV) Director Sharon Wienbar Purchases 907 Shares of Stock

Enovis Corporation (NYSE:ENOV) Director Sharon Wienbar purchased 907 shares of the business’s stock in a transaction that occurred on Friday, November 6th. The stock was acquired at an average price of $27.55 per share, with a total value of $24,987.85. Following the purchase, the director owned 42,853 shares in the company, valued at $1,180,600.15. This represents a 2.16% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Enovis Stock Performance

ENOV opened at $28.25 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 2.15 and a debt-to-equity ratio of 0.82. The company has a market cap of $1.63 billion, a price-to-earnings ratio of 8.44 and a beta of 1.31. Enovis Corporation has a 52-week low of $16.70 and a 52-week high of $32.41. The firm’s fifty day simple moving average is $20.05 and its two-hundred day simple moving average is $23.14.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.11. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The firm had revenue of $558.73 million for the quarter, compared to analyst estimates of $557.12 million. During the same period in the previous year, the company posted $0.75 earnings per share. The business’s revenue was up 1.8% on a year-over-year basis. Equities analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. UBS Group reaffirmed a “buy” rating and set a $44.00 price target on shares of Enovis in a research report on Monday, October 5th. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Citizens Jmp cut their target price on Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research note on Wednesday, September 2nd. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Finally, Canaccord Genuity Group decreased their price target on Enovis from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Friday, November 6th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Enovis has an average rating of “Moderate Buy” and a consensus target price of $38.62.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. IFP Advisors Inc grew its stake in shares of Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after purchasing an additional 1,174 shares in the last quarter. Allworth Financial LP acquired a new stake in Enovis in the second quarter valued at $36,000. Integrated Wealth Concepts LLC acquired a new stake in Enovis in the second quarter valued at $39,000. Public Employees Retirement System of Ohio purchased a new stake in Enovis during the 2nd quarter worth about $48,000. Finally, SBI Securities Co. Ltd. purchased a new stake in Enovis during the 3rd quarter worth about $55,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

About Enovis

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.